TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Regorafenib in Relapsed Glioblastoma REGOMA Study Randomized, Controlled Open-label Phase II Clinical Trial
Brief Summary: This study aims to evaluate the role of Regorafenib in prolonging the overall survival of glioblastoma multiforme patients who progressed after surgery and Stupp regimen with or without bevacizumab.


Options:
A: Arm Label: Arm A: AA-PET based target volume delineation; Type: EXPERIMENTAL; Interventions: Radiation: Radiation Therapy | Arm Label: Arm B: T1Gd-MRI based target volume delineation; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Radiation Therapy | Intervention Type: RADIATION; Name: Radiation Therapy; Assigned to Arm(s): Arm A: AA-PET based target volume delineation | Intervention Type: RADIATION; Name: Radiation Therapy; Assigned to Arm(s): Arm B: T1Gd-MRI based target volume delineation
B: Arm Label: Temozolomide; Type: ACTIVE_COMPARATOR; Interventions: Drug: temozolomide, Genetic: DNA methylation analysis, Procedure: quality-of-life assessment | Arm Label: Radiation; Type: ACTIVE_COMPARATOR; Interventions: Genetic: DNA methylation analysis, Procedure: quality-of-life assessment, Radiation: Radiation | Intervention Type: DRUG; Name: temozolomide; Assigned to Arm(s): Temozolomide | Intervention Type: GENETIC; Name: DNA methylation analysis; Assigned to Arm(s): Radiation, Temozolomide | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): Radiation, Temozolomide | Intervention Type: RADIATION; Name: Radiation; Assigned to Arm(s): Radiation
C: Arm Label: NovoTTF-100A device in combination with Temozolomide; Type: EXPERIMENTAL; Interventions: Device: NovoTTF-100A device | Arm Label: Temozolomide alone, as the best known standard of care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Temozolomide | Intervention Type: DEVICE; Name: NovoTTF-100A device; Assigned to Arm(s): NovoTTF-100A device in combination with Temozolomide | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Temozolomide alone, as the best known standard of care
D: Arm Label: ARM A - Regorafenib; Type: EXPERIMENTAL; Interventions: Drug: Regorafenib | Arm Label: ARM B - Lomustine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lomustine | Intervention Type: DRUG; Name: Regorafenib; Assigned to Arm(s): ARM A - Regorafenib | Intervention Type: DRUG; Name: Lomustine; Assigned to Arm(s): ARM B - Lomustine

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Low Calorie Sweetener Consumption on Body Weight, Body Composition, Appetite, and Energy Intake
Brief Summary: The aim of this study will be to compare the effects of daily consumption of aspartame, rebaudioside a, saccharin, sucralose, and sucrose on body weight and composition in a standardized protocol. The investigators hypothesize that individual low calorie sweeteners (consumed in a beverage) differ from each other in promoting weight loss and decreased fat mass (without energy restriction or dietary guidance) based on their chemical structure.


Options:
A: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A
B: Arm Label: Sucrose Sweetened Beverage; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Beverage | Arm Label: Aspartame Sweetened Beverage; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Beverage | Arm Label: Saccharin Sweetened Beverage; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Beverage | Arm Label: Sucralose Sweetened Beverage; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Beverage | Arm Label: Rebaudioside A Sweeteened Beverage; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Beverage | Intervention Type: DIETARY_SUPPLEMENT; Name: Beverage; Assigned to Arm(s): Aspartame Sweetened Beverage, Rebaudioside A Sweeteened Beverage, Saccharin Sweetened Beverage, Sucralose Sweetened Beverage, Sucrose Sweetened Beverage
C: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: intervention group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: artificially sweetened beverages | Intervention Type: DIETARY_SUPPLEMENT; Name: artificially sweetened beverages; Assigned to Arm(s): intervention group
D: Arm Label: Sucrose; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Sucrose | Arm Label: Aspartame; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Aspartame | Intervention Type: DIETARY_SUPPLEMENT; Name: Sucrose; Assigned to Arm(s): Sucrose | Intervention Type: DIETARY_SUPPLEMENT; Name: Aspartame; Assigned to Arm(s): Aspartame

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of a Mindfulness Intervention Delivered Within Diabetes Education on Diabetes-related Outcomes in Military Veterans
Brief Summary: The purpose of this study is to see if adding Mindfulness training to diabetes education reduces feelings of stress and makes it easier to adhere to healthy behaviors that improve diabetes outcomes (such as hemoglobin A1c).


Options:
A: Arm Label: FACT Module Engagement; Type: EXPERIMENTAL; Interventions: Behavioral: FACT Module Engagement | Arm Label: FACT Module Openness; Type: EXPERIMENTAL; Interventions: Behavioral: FACT Module Openness | Arm Label: FACT Module Awareness; Type: EXPERIMENTAL; Interventions: Behavioral: FACT Module Awareness | Intervention Type: BEHAVIORAL; Name: FACT Module Engagement; Assigned to Arm(s): FACT Module Engagement | Intervention Type: BEHAVIORAL; Name: FACT Module Openness; Assigned to Arm(s): FACT Module Openness | Intervention Type: BEHAVIORAL; Name: FACT Module Awareness; Assigned to Arm(s): FACT Module Awareness
B: Arm Label: Mindfulness; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness-based intervention | Arm Label: Sham meditation; Type: SHAM_COMPARATOR; Interventions: Behavioral: Sham meditation | Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mindfulness-based intervention; Assigned to Arm(s): Mindfulness | Intervention Type: BEHAVIORAL; Name: Sham meditation; Assigned to Arm(s): Sham meditation
C: Arm Label: Diabetes Self Management Education (DSME) + Mind-STRIDE; Type: EXPERIMENTAL; Interventions: Behavioral: Mind-STRIDE | Arm Label: DSME alone; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mind-STRIDE; Assigned to Arm(s): Diabetes Self Management Education (DSME) + Mind-STRIDE
D: Arm Label: Walking meditation & Walking; Type: EXPERIMENTAL; Interventions: Other: Walking Meditation, Other: Walking | Arm Label: Walking meditation & No exercise; Type: ACTIVE_COMPARATOR; Interventions: Other: Walking Meditation, Other: No exercise | Intervention Type: OTHER; Name: Walking Meditation; Assigned to Arm(s): Walking meditation & No exercise, Walking meditation & Walking | Intervention Type: OTHER; Name: Walking; Assigned to Arm(s): Walking meditation & Walking | Intervention Type: OTHER; Name: No exercise; Assigned to Arm(s): Walking meditation & No exercise

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to investigate the effects of coffee main constituents (caffeine and chlorogenic acid) supplements on inflammatory, metabolic factors, hepatic steatosis and fibrosis in none- alcoholic fatty liver patients with type 2 diabetes. Two hundred patients with fatty liver and type 2 diabetes will be randomly assigned to one of four groups: group 1, caffeine (200 mg/d) plus chlorogenic acid (200 mg/d); group 2, caffeine (200 mg/d) plus placebo; group 3, chlorogenic acid (200 mg/d) plus placebo; group 4, placebo plus placebo. Supplementation will be daily and will supervise for 6 months.


Options:
A: Arm Label: TREATED GROUP; Type: EXPERIMENTAL; Interventions: Drug: Hydroxytyrosol plus Vitamin E | Arm Label: PLACEBO GROUP; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Hydroxytyrosol plus Vitamin E; Assigned to Arm(s): TREATED GROUP | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): PLACEBO GROUP
B: Arm Label: Omega 3 recipient arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Omega 3 Fish Oil supplements | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Omega 3 Fish Oil supplements; Assigned to Arm(s): Omega 3 recipient arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: caffeine and chlorogeinc acid; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: caffeine and chlorogenic acid | Arm Label: caffeine; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: caffeine | Arm Label: chlorogenic acid; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: chlorogenic acid | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: caffeine and chlorogenic acid; Assigned to Arm(s): caffeine and chlorogeinc acid | Intervention Type: DIETARY_SUPPLEMENT; Name: caffeine; Assigned to Arm(s): caffeine | Intervention Type: DIETARY_SUPPLEMENT; Name: chlorogenic acid; Assigned to Arm(s): chlorogenic acid | Intervention Type: DIETARY_SUPPLEMENT; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: Sillymarin; Type: EXPERIMENTAL; Interventions: Drug: Sillymarin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sillymarin; Assigned to Arm(s): Sillymarin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
Brief Summary: A Study to evaluate efficacy and safety in subjects with moderate to severe Psoriasis treated with BMS-986165


Options:
A: Arm Label: Placebo (Part A); Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo for risankizumab, Drug: placebo for ustekinumab | Arm Label: Ustekinumab (Part A); Type: ACTIVE_COMPARATOR; Interventions: Drug: placebo for risankizumab, Drug: ustekinumab | Arm Label: Risankizumab (Part A); Type: EXPERIMENTAL; Interventions: Drug: risankizumab, Drug: placebo for ustekinumab | Intervention Type: DRUG; Name: risankizumab; Assigned to Arm(s): Risankizumab (Part A) | Intervention Type: DRUG; Name: placebo for risankizumab; Assigned to Arm(s): Placebo (Part A), Ustekinumab (Part A) | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): Ustekinumab (Part A) | Intervention Type: DRUG; Name: placebo for ustekinumab; Assigned to Arm(s): Placebo (Part A), Risankizumab (Part A)
B: Arm Label: Group A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Drug: Etanercept + Acitretin | Arm Label: Group C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acitretin | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Group A | Intervention Type: DRUG; Name: Etanercept + Acitretin; Assigned to Arm(s): Group B | Intervention Type: DRUG; Name: Acitretin; Assigned to Arm(s): Group C
C: Arm Label: BMS-986165 Dose 1; Type: EXPERIMENTAL; Interventions: Drug: BMS-986165 | Arm Label: BMS-986165 Dose 2; Type: EXPERIMENTAL; Interventions: Drug: BMS-986165 | Arm Label: BMS-986165 Dose 3; Type: EXPERIMENTAL; Interventions: Drug: BMS-986165 | Arm Label: BMS-986165 Dose 4; Type: EXPERIMENTAL; Interventions: Drug: BMS-986165 | Arm Label: BMS-986165 Dose 5; Type: EXPERIMENTAL; Interventions: Drug: BMS-986165 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for BMS-986165 | Intervention Type: DRUG; Name: BMS-986165; Assigned to Arm(s): BMS-986165 Dose 1, BMS-986165 Dose 2, BMS-986165 Dose 3, BMS-986165 Dose 4, BMS-986165 Dose 5 | Intervention Type: DRUG; Name: Placebo for BMS-986165; Assigned to Arm(s): Placebo
D: Arm Label: Etanercept 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Etanercept | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Etanercept 50 mg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis
Brief Summary: A Study to evaluate efficacy and safety in subjects with moderate to severe Psoriasis treated with BMS-986165


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: etanercept | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: etanercept, Drug: Placebo | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): B | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
B: Arm Label: 80 mg Ixekizumab Auto-Injector; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab Auto-Injector | Arm Label: 80 mg Ixekizumab Prefilled Syringe; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab Prefilled Syringe | Intervention Type: DRUG; Name: Ixekizumab Auto-Injector; Assigned to Arm(s): 80 mg Ixekizumab Auto-Injector | Intervention Type: DRUG; Name: Ixekizumab Prefilled Syringe; Assigned to Arm(s): 80 mg Ixekizumab Prefilled Syringe
C: Arm Label: BMS-986165 Dose 1; Type: EXPERIMENTAL; Interventions: Drug: BMS-986165 | Arm Label: BMS-986165 Dose 2; Type: EXPERIMENTAL; Interventions: Drug: BMS-986165 | Arm Label: BMS-986165 Dose 3; Type: EXPERIMENTAL; Interventions: Drug: BMS-986165 | Arm Label: BMS-986165 Dose 4; Type: EXPERIMENTAL; Interventions: Drug: BMS-986165 | Arm Label: BMS-986165 Dose 5; Type: EXPERIMENTAL; Interventions: Drug: BMS-986165 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for BMS-986165 | Intervention Type: DRUG; Name: BMS-986165; Assigned to Arm(s): BMS-986165 Dose 1, BMS-986165 Dose 2, BMS-986165 Dose 3, BMS-986165 Dose 4, BMS-986165 Dose 5 | Intervention Type: DRUG; Name: Placebo for BMS-986165; Assigned to Arm(s): Placebo
D: Arm Label: 210 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 210 mg brodalumab | Arm Label: 140 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 140 mg brodalumab | Arm Label: ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 210 mg brodalumab, Drug: placebo | Intervention Type: DRUG; Name: 210 mg brodalumab; Assigned to Arm(s): 210 mg brodalumab, Placebo | Intervention Type: DRUG; Name: 140 mg brodalumab; Assigned to Arm(s): 140 mg brodalumab | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): ustekinumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Health Effects of oraL Protein Supplements in HD (The HELPS-HD Trial) An Open-Label Cluster Randomized Pragmatic Trial Evaluating the Effectiveness of Oral Intradialytic Nutritional Supplements on Mortality in Hemodialysis Patients
Brief Summary: To conduct a pragmatic randomized clinical trial in which the researchers will determine the mortality impact of a protocol whereby all hemodialysis patients receive an oral, protein-based nutritional supplement during the dialysis procedure as compared to the existing nutritional protocol whereby only hemodialysis patients with serum albumin below 3.5 g/dL and incident hemodialysis patients during the first months of care receive an oral, intradialytic protein-based nutritional supplement during the dialysis procedure.


Options:
A: Arm Label: Usual Care Protocol; Type: OTHER; Interventions: Dietary Supplement: Nutritional Supplement | Arm Label: Intensive Protocol; Type: OTHER; Interventions: Dietary Supplement: Nutritional Supplement | Intervention Type: DIETARY_SUPPLEMENT; Name: Nutritional Supplement; Assigned to Arm(s): Intensive Protocol, Usual Care Protocol
B: Arm Label: Standard of Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard of Care | Arm Label: Nepro with Carb Steady; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Nepro with Carb Steady | Intervention Type: DIETARY_SUPPLEMENT; Name: Nepro with Carb Steady; Assigned to Arm(s): Nepro with Carb Steady | Intervention Type: OTHER; Name: Standard of Care; Assigned to Arm(s): Standard of Care
C: Arm Label: whey drink; Type: EXPERIMENTAL; Interventions: Dietary Supplement: whey drink, | Arm Label: whey drink fortified with vitaminE; Type: EXPERIMENTAL; Interventions: Dietary Supplement: whey drink fortified with vitaminE | Arm Label: vitaminE; Type: EXPERIMENTAL; Interventions: Dietary Supplement: vitamin E | Arm Label: D- control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: whey drink,; Assigned to Arm(s): whey drink | Intervention Type: DIETARY_SUPPLEMENT; Name: whey drink fortified with vitaminE; Assigned to Arm(s): whey drink fortified with vitaminE | Intervention Type: DIETARY_SUPPLEMENT; Name: vitamin E; Assigned to Arm(s): vitaminE
D: Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Dietary Supplement: Control | Arm Label: Protein; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Protein | Arm Label: Protein + Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Protein + Exercise | Intervention Type: DIETARY_SUPPLEMENT; Name: Control; Assigned to Arm(s): Control | Intervention Type: DIETARY_SUPPLEMENT; Name: Protein; Assigned to Arm(s): Protein | Intervention Type: BEHAVIORAL; Name: Protein + Exercise; Assigned to Arm(s): Protein + Exercise

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Safety Study Assessing Oral Anticoagulation With Apixaban Versus Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD) on Chronic Hemodialysis Treatment
Brief Summary: The Study is an open-labeled, randomized controlled trial, phase IIIb. Its objective is to assess the safety of the factor Xa inhibitor apixaban versus the vitamin-K antagonist (VKA) phenprocoumon in patients with NVAF and ESKD on hemodialysis. The safety will be assessed by means of the incidence of major and clinically relevant, non-major bleeding on anticoagulation.


Options:
A: Arm Label: Vitamin K antagonist; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: rivaroxaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: rivaroxaban | Arm Label: rivaroxaban and vitamin K2; Type: ACTIVE_COMPARATOR; Interventions: Drug: rivaroxaban, Dietary Supplement: Vitamin K2 | Intervention Type: DRUG; Name: rivaroxaban; Assigned to Arm(s): rivaroxaban, rivaroxaban and vitamin K2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin K2; Assigned to Arm(s): rivaroxaban and vitamin K2
B: Arm Label: AD- acetic acid dialysate; Type: ACTIVE_COMPARATOR; Interventions: Other: acetic-acid based dialysate (AD) | Arm Label: CD - citrasate dialysate; Type: EXPERIMENTAL; Interventions: Other: citrate dialysate (CD) | Intervention Type: OTHER; Name: citrate dialysate (CD); Assigned to Arm(s): CD - citrasate dialysate | Intervention Type: OTHER; Name: acetic-acid based dialysate (AD); Assigned to Arm(s): AD- acetic acid dialysate
C: Arm Label: Tinzaparin; Type: EXPERIMENTAL; Interventions: Drug: Tinzaparin administration | Arm Label: Heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin administration | Intervention Type: DRUG; Name: Tinzaparin administration; Assigned to Arm(s): Tinzaparin | Intervention Type: DRUG; Name: Heparin administration; Assigned to Arm(s): Heparin
D: Arm Label: Apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Vitamin-K antagonists (Phenprocoumon); Type: ACTIVE_COMPARATOR; Interventions: Drug: Phenprocoumon | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Phenprocoumon; Assigned to Arm(s): Vitamin-K antagonists (Phenprocoumon)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Autologous T Cells With a Chimeric Antigen Receptor in Patients With CD19-positive Malignant B Cell Leukemia and Lymphoma
Brief Summary: This study is designed for determining the safety and relative engraftment levels of the redirected autologous T cells transduced with the anti-CD19 lentiviral vector in patients with CD19-positive B cell leukemia and malignant lymphoma.


Options:
A: Arm Label: Treatment Regimen; Type: EXPERIMENTAL; Interventions: Drug: Fludarabine, Drug: Cyclophosphamide, Biological: anti-CD19 CAR-T cells | Intervention Type: DRUG; Name: Fludarabine; Assigned to Arm(s): Treatment Regimen | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Treatment Regimen | Intervention Type: BIOLOGICAL; Name: anti-CD19 CAR-T cells; Assigned to Arm(s): Treatment Regimen
B: Arm Label: CD19-7×19 CAR-T plus PD1 monoclonal antibody; Type: EXPERIMENTAL; Interventions: Biological: CD19-7×19 CAR-T plus PD1 monoclonal antibody | Intervention Type: BIOLOGICAL; Name: CD19-7×19 CAR-T plus PD1 monoclonal antibody; Assigned to Arm(s): CD19-7×19 CAR-T plus PD1 monoclonal antibody
C: Arm Label: Axicabtagene Ciloleucel and Rituximab Combination; Type: EXPERIMENTAL; Interventions: Biological: Axicabtagene Ciloleucel, Drug: Rituximab, Drug: Fludarabine, Drug: Cyclophosphamide | Intervention Type: BIOLOGICAL; Name: Axicabtagene Ciloleucel; Assigned to Arm(s): Axicabtagene Ciloleucel and Rituximab Combination | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Axicabtagene Ciloleucel and Rituximab Combination | Intervention Type: DRUG; Name: Fludarabine; Assigned to Arm(s): Axicabtagene Ciloleucel and Rituximab Combination | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Axicabtagene Ciloleucel and Rituximab Combination
D: Arm Label: CAR-CD19 T cells; Type: EXPERIMENTAL; Interventions: Genetic: CAR-CD19 T cells, Drug: Fludarabine, Drug: Cyclophosphamide | Intervention Type: GENETIC; Name: CAR-CD19 T cells; Assigned to Arm(s): CAR-CD19 T cells | Intervention Type: DRUG; Name: Fludarabine; Assigned to Arm(s): CAR-CD19 T cells | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): CAR-CD19 T cells

Answer: D